Pageview Pharmaceuticals

Pageview Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapies for cancer. The company's lead program, PV-001, is a highly selective inhibitor of Cyclin-dependent kinase 9 (CDK9), a key regulator of transcriptional elongation that is often dysregulated in various malignancies. Pageview is currently evaluating PV-001 in Phase 1/2 clinical trials for patients with relapsed or refractory acute myeloid leukemia and advanced solid tumors. Headquartered in South San Francisco with operations in China, the company leverages its expertise in medicinal chemistry and cancer biology to advance its pipeline of targeted oncology treatments. Pageview aims to provide new therapeutic options for patients who have exhausted standard-of-care treatments.